Jian Chen1,2,3, Hongwei Hou3, Huan Chen3, Yanbo Luo3, Yunlu He3, Lirong Zhang4, Yunfei Zhang5, Hansong Liu6, Fangfang Zhang6, Yong Liu1, An Wang1, Qingyuan Hu3. 1. Institute of Applied Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei 230031, Anhui, PR China. 2. Graduate school, University of Science & Technology of China, Hefei 230026, Anhui, PR China. 3. Quality Safety and Framework Convention on Tobacco Control Research Team, China National Tobacco Quality Supervision & Test Center, Zhengzhou 450001, Henan, PR China. 4. School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, Henan, PR China. 5. Henan Cancer Hospital, Zhengzhou University, Zhengzhou 450008, Henan, PR China. 6. Zhengzhou Central Hospital affiliated to Zhengzhou University, Zhengzhou 450001, Henan, PR China.
Abstract
Aim: β-Hydroxybutyrate (BHB) was proved to be a differential metabolite of papillary thyroid cancer (PTC) by semiquantitative analysis, while whether BHB could be used as a potential biomarker for female PTC still needed to be validated. Materials & methods: An LC-MS/MS method with surrogate matrix was established to validate serum BHB in specified PTC patients. Conclusion: Serum BHB levels in PTCs were significantly higher than those in HCs. For both serum BHB with a cut-off value of 312.5 ng/ml and serum BHB/creatinine of 33.5 μmol/mmol, a promising prediction rate to distinguish low-grade PTCs from HCs with satisfactory sensitivity and specificity was achieved, indicating that serum BHB might be proved as a useful biomarker for low-grade female PTC.
Aim: β-Hydroxybutyrate (BHB) was proved to be a differential metabolite of papillary thyroid cancer (PTC) by semiquantitative analysis, while whether BHB could be used as a potential biomarker for female PTC still needed to be validated. Materials & methods: An LC-MS/MS method with surrogate matrix was established to validate serum BHB in specified PTC patients. Conclusion: Serum BHB levels in PTCs were significantly higher than those in HCs. For both serum BHB with a cut-off value of 312.5 ng/ml and serum BHB/creatinine of 33.5 μmol/mmol, a promising prediction rate to distinguish low-grade PTCs from HCs with satisfactory sensitivity and specificity was achieved, indicating that serum BHB might be proved as a useful biomarker for low-grade female PTC.
Authors: Kelechi Njoku; Amy E Campbell; Bethany Geary; Michelle L MacKintosh; Abigail E Derbyshire; Sarah J Kitson; Vanitha N Sivalingam; Andrew Pierce; Anthony D Whetton; Emma J Crosbie Journal: Cancers (Basel) Date: 2021-02-10 Impact factor: 6.575